UK to start human trials of coronavirus vaccine on Thursday, Germany approves first human trials
Oxford University’s Jenner Institute is developing a potential coronavirus vaccine for which the human trials will begin n Thursday, 23rd April 2020.
Reportedly, the UK government will be providing £20 million ($24 million) to the university’s team and a further £22.5 million to Imperial College, where scientists are also working on a vaccine.
Secretary of State for Health and Social Care Matt Hancock shared that the coronavirus vaccine developed by Oxford University will enter human trials as early as this Thursday as the UK throws everything at vital breakthrough.
He also praised both teams for making rapid progress amid the coronavirus pandemic.
“The vaccine from the Oxford [University] project will be trialled in people from this Thursday”
Health Secretary Matt Hancock announces £20m funding for the research, saying “in normal times reaching this stage would take years”
— BBC News (UK) (@BBCNews) April 21, 2020
Matt Hancock further shared that the UK government would invest in manufacturing capabilities so that if either vaccine was successful it could be available for British people as soon as possible.
Scientists at Oxford have previously aimed to produce a million doses of the vaccine by September 2020.
Director of Oxford University’s Jenner Institute Adrian Hill said in March that their team had the exceptional experience of rapid vaccine response, such as to the Ebola outbreak in West Africa in 2014
“Vaccines are being designed from scratch and progressed at an unprecedented rate. The upcoming trial will be critical for assessing the feasibility of vaccination against COVID-19 and could lead to early deployment.”
Coronavirus vaccine: Germany approves first human trials
On the other hand, Germany has also approved for the clinical test of a COVID-19 vaccine on Wednesday, according to the country’s Federal Institute for Vaccines.
The first human trials will include 200 healthy participants between the age of 18 and 55 who will receive several variants of the vaccine, developed by German biotech company BioNTech.
Hopeful news from Germany. @BioNTech_Group gets the go ahead to begin clinical trials for its mRNA Covid-19 vaccine.
— Joe Miller (@JoeMillerJr) April 22, 2020
These trials will determine the efficacy of the potential vaccine in providing immunity against the virus.
Additional tests will be conducted on more people, including those at higher risk from the disease, in a second stage of the trial.
Have something to add to the story? Let us know in the comments below.
Stay tuned to Hit in Pakistan for more updates and news!